NanoBio Corp., of Ann Arbor, Mich., began two Phase III trials of NB-001 for cold sores, as part of its 2009 licensing agreement with GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline plc, of London. The trials will enroll a total of 1,700 subjects at 72 clinical sites, and are expected to conclude in 2012.